Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating
Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.